Deborah Cragun1, Rita D DeBate2, Susan T Vadaparampil1, Julie Baldwin2, Heather Hampel3, Tuya Pal1. 1. Division of Population Science, Moffitt Cancer Center, Tampa, Florida, USA. 2. Department of Community and Family Health, University of South Florida, Tampa, Florida, USA. 3. Department of Internal Medicine, Ohio State University, Columbus, Ohio, USA.
Abstract
PURPOSE: Universal tumor screening (UTS) for all colorectal cancer patients can improve the identification of Lynch syndrome, the most common cause of hereditary colorectal cancer. This multiple-case study explored how variability in UTS procedures influenced patient follow-through (PF) with germ-line testing after a screen-positive result. METHODS: Data were obtained through Web-based surveys and telephone interviews with institutional informants. Institutions were categorized as Low-PF (≤10% underwent germ-line testing), Medium-PF (11-40%), or High-PF (>40%). To identify implementation procedures (i.e., conditions) unique to High-PF institutions, qualitative comparative analysis was performed. RESULTS: Twenty-one informants from 15 institutions completed surveys and/or interviews. Conditions present among all five High-PF institutions included the following: (i) disclosure of screen-positive results to patients by genetic counselors; and (ii) genetic counselors either facilitate physician referrals to genetics professionals or eliminate the need for referrals. Although both of these High-PF conditions were present among two Medium-PF institutions, automatic reflex testing was lacking and difficulty contacting screen-positive patients was a barrier. The three remaining Medium-PF and five Low-PF institutions lacked the conditions found in High-PF institutions. CONCLUSION: METHODS for streamlining UTS procedures, incorporating a high level of involvement of genetic counselors in tracking and communication of results and in reducing barriers to patient contact, are reviewed within a broader discussion on maximizing the effectiveness and public health impact of UTS.
PURPOSE: Universal tumor screening (UTS) for all colorectal cancer patients can improve the identification of Lynch syndrome, the most common cause of hereditary colorectal cancer. This multiple-case study explored how variability in UTS procedures influenced patient follow-through (PF) with germ-line testing after a screen-positive result. METHODS: Data were obtained through Web-based surveys and telephone interviews with institutional informants. Institutions were categorized as Low-PF (≤10% underwent germ-line testing), Medium-PF (11-40%), or High-PF (>40%). To identify implementation procedures (i.e., conditions) unique to High-PF institutions, qualitative comparative analysis was performed. RESULTS: Twenty-one informants from 15 institutions completed surveys and/or interviews. Conditions present among all five High-PF institutions included the following: (i) disclosure of screen-positive results to patients by genetic counselors; and (ii) genetic counselors either facilitate physician referrals to genetics professionals or eliminate the need for referrals. Although both of these High-PF conditions were present among two Medium-PF institutions, automatic reflex testing was lacking and difficulty contacting screen-positive patients was a barrier. The three remaining Medium-PF and five Low-PF institutions lacked the conditions found in High-PF institutions. CONCLUSION: METHODS for streamlining UTS procedures, incorporating a high level of involvement of genetic counselors in tracking and communication of results and in reducing barriers to patient contact, are reviewed within a broader discussion on maximizing the effectiveness and public health impact of UTS.
Authors: Jane Morrison; Mary Bronner; Brandie H Leach; Erinn Downs-Kelly; John R Goldblum; Xiuli Liu Journal: Scand J Gastroenterol Date: 2011-08-31 Impact factor: 2.423
Authors: Heather Hampel; Julie A Stephens; Eero Pukkala; Risto Sankila; Lauri A Aaltonen; Jukka-Pekka Mecklin; Albert de la Chapelle Journal: Gastroenterology Date: 2005-08 Impact factor: 22.682
Authors: Muin J Khoury; Michael S Bowen; Wylie Burke; Ralph J Coates; Nicole F Dowling; James P Evans; Michele Reyes; Jeannette St Pierre Journal: Am J Prev Med Date: 2011-04 Impact factor: 5.043
Authors: Laura J Damschroder; David C Aron; Rosalind E Keith; Susan R Kirsh; Jeffery A Alexander; Julie C Lowery Journal: Implement Sci Date: 2009-08-07 Impact factor: 7.327
Authors: Patrice Watson; Hans F A Vasen; Jukka-Pekka Mecklin; Inge Bernstein; Markku Aarnio; Heikki J Järvinen; Torben Myrhøj; Lone Sunde; Juul T Wijnen; Henry T Lynch Journal: Int J Cancer Date: 2008-07-15 Impact factor: 7.396
Authors: Matthew B Yurgelun; Brian Allen; Rajesh R Kaldate; Karla R Bowles; Thaddeus Judkins; Praveen Kaushik; Benjamin B Roa; Richard J Wenstrup; Anne-Renee Hartman; Sapna Syngal Journal: Gastroenterology Date: 2015-05-14 Impact factor: 22.682
Authors: Mujde Z Erten; Luca P Fernandez; Hank K Ng; Wendy C McKinnon; Brandie Heald; Christopher J Koliba; Marc S Greenblatt Journal: Dig Dis Sci Date: 2016-07-06 Impact factor: 3.199